Literature DB >> 11160854

Role of an inverted CCAAT element in human topoisomerase IIalpha gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells.

S E Morgan1, W T Beck.   

Abstract

DNA topoisomerase (topo) IIalpha gene expression or activity is altered in tumor cells selected for resistance to inhibitors of topoII. To better understand the mechanisms by which topoIIalpha expression levels are modulated, we examined topoIIalpha transcriptional regulation in ICRF-187-sensitive and ICRF-187-resistant human leukemic cell lines that express an increased amount of topoIIalpha protein and mRNA. Transient transfections of luciferase reporter plasmids containing either the full-length human topoIIalpha promoter or fragments of it revealed that topoIIalpha transcriptional activity was significantly increased in the drug-resistant CEM/ICRF-8 cells, compared with CEM cells. Specifically, the transcriptional activity of the full-length topoIIalpha promoter (nucleotides -557 to +90) was doubled in CEM/ICRF-8 compared with CEM cells. Serial deletion of the topoIIalpha promoter permitted localization of the region responsible for its up-regulation in the drug-resistant cells between nucleotides -557 and -162, which includes the last three inverted CCAAT elements (ICE) 3 to 5. Note that construction of a point mutation in ICE3 resulted in a significant increase in transcriptional activity of the topoIIalpha promoter in the drug-sensitive CEM cells. In addition, by electrophoretic mobility shift assay, ICE3 was recognized by a protein complex containing NF-YB that was present at reduced levels in the topoIIalpha-overexpressing CEM/ICRF-8 extracts, suggesting that ICE3 plays a negative regulatory role in human topoIIalpha gene expression. This is the first study to show that topoIIalpha transcriptional up-regulation in ICRF-187-resistant cells is mediated in part by altered regulation of the third inverted CCAAT box in the topoIIalpha promoter.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160854     DOI: 10.1124/mol.59.2.203

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  5 in total

1.  Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells.

Authors:  Sungpil Cho; Meiling Lu; Xiaolong He; Pui-Lai Rachel Ee; Uppoor Bhat; Erasmus Schneider; Lucio Miele; William T Beck
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

2.  Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIα and drug responsiveness.

Authors:  Cheng-Fen Chen; Xiaolong He; Ahmet Dirim Arslan; Yin-Yuan Mo; William C Reinhold; Yves Pommier; William T Beck
Journal:  Mol Pharmacol       Date:  2011-01-20       Impact factor: 4.436

3.  Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.

Authors:  Chun-Nam Lok; Alexander J Lang; Shelagh E L Mirski; Susan P C Cole
Journal:  Biochem J       Date:  2002-12-15       Impact factor: 3.857

Review 4.  Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer.

Authors:  Michihiko Kuwano; Tomohiro Shibata; Kosuke Watari; Mayumi Ono
Journal:  Cancer Sci       Date:  2019-04-07       Impact factor: 6.716

5.  HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha.

Authors:  Michal Stros; Eva Polanská; Sona Struncová; Sárka Pospísilová
Journal:  Nucleic Acids Res       Date:  2009-02-17       Impact factor: 16.971

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.